Synaptogenix Inc (NASDAQ:SNPX) — Market Cap & Net Worth
Market Cap & Net Worth: Synaptogenix Inc (SNPX)
Synaptogenix Inc (NASDAQ:SNPX) has a market capitalization of $8.09 Million ($8.09 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27555 globally and #5619 in its home market, demonstrating a -9.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Synaptogenix Inc's stock price $5.82 by its total outstanding shares 1389820 (1.39 Million). Review how much debt does Synaptogenix Inc carry to assess the company's total debt and financial obligations.
Synaptogenix Inc Market Cap History: 2020 to 2025
Synaptogenix Inc's market capitalization history from 2020 to 2025. Data shows change from $208.47 Million to $8.09 Million (-43.44% CAGR).
Index Memberships
Synaptogenix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #796 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2570 of 3165 |
Weight: Synaptogenix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Synaptogenix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Synaptogenix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SNPX by Market Capitalization
Companies near Synaptogenix Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Synaptogenix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Synaptogenix Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Synaptogenix Inc's market cap moved from $208.47 Million to $ 8.09 Million, with a yearly change of -43.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $8.09 Million | +67.72% |
| 2024 | $4.82 Million | -48.97% |
| 2023 | $9.45 Million | -76.55% |
| 2022 | $40.30 Million | -86.37% |
| 2021 | $295.68 Million | +41.83% |
| 2020 | $208.47 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Synaptogenix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.09 Million USD |
| MoneyControl | $8.09 Million USD |
| MarketWatch | $8.09 Million USD |
| marketcap.company | $8.09 Million USD |
| Reuters | $8.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more